Coherus Biosciences | CHRS - Trade Debtors


Coherus Biosciences reported $18.42M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
AbbVie USD 12.59B 180M Dec/2025
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
ALKERMES USD 407.63M 73.6M Mar/2026
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Amarin USD 126.83M 477K Dec/2025
Amgen USD 9.14B 432M Mar/2026
Baxter International USD 1.7B 310M Mar/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Eli Lilly USD 21.18B 1.02B Mar/2026
Fujifilm JPY 887.02B 64.37B Mar/2026
Gilead Sciences USD 4.74B 172M Mar/2026
Ironwood Pharmaceuticals USD 81.89M 5.68M Dec/2024
Merck USD 11.78B 345M Dec/2025
Myriad Genetics USD 115.3M 2.7M Dec/2025
Pacira USD 125.64M 1.57M Mar/2026
Perrigo USD 697.1M 84.3M Mar/2026
Pfizer USD 16.17B 332M Mar/2026
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Teva Pharmaceutical Industries USD 3.39B 316M Mar/2026
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026
Xencor USD 12M 17.3M Mar/2026
Zoetis USD 1.51B 84M Mar/2026